Although amylin's self-aggregation property under the pathlogical conditions (Pillay and Govender, 2013) may affect its development as a drug for AD, several studies demonstrate that amylin can inhibit Aβ aggregate, as they can form the cross-interactions (Andreetto et al., 2010; Seeliger et al., 2012). This evidence concerns the gene IAPP and Alzheimer disease.